<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://pharmacopedia.wiki/index.php?action=history&amp;feed=atom&amp;title=Cefuroxime</id>
	<title>Cefuroxime - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://pharmacopedia.wiki/index.php?action=history&amp;feed=atom&amp;title=Cefuroxime"/>
	<link rel="alternate" type="text/html" href="https://pharmacopedia.wiki/index.php?title=Cefuroxime&amp;action=history"/>
	<updated>2026-05-28T12:10:30Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.46.0-beta</generator>
	<entry>
		<id>https://pharmacopedia.wiki/index.php?title=Cefuroxime&amp;diff=6871&amp;oldid=prev</id>
		<title>MDElliottMD: home-claude category backfill (parser-claude gap closure)</title>
		<link rel="alternate" type="text/html" href="https://pharmacopedia.wiki/index.php?title=Cefuroxime&amp;diff=6871&amp;oldid=prev"/>
		<updated>2026-05-23T10:43:40Z</updated>

		<summary type="html">&lt;p&gt;home-claude category backfill (parser-claude gap closure)&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw-interface=&quot;&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 10:43, 23 May 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l21&quot;&gt;Line 21:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 21:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references /&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[Category:Cephalosporins]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[Category:Beta-lactam antibiotics]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>MDElliottMD</name></author>
	</entry>
	<entry>
		<id>https://pharmacopedia.wiki/index.php?title=Cefuroxime&amp;diff=6455&amp;oldid=prev</id>
		<title>MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #279</title>
		<link rel="alternate" type="text/html" href="https://pharmacopedia.wiki/index.php?title=Cefuroxime&amp;diff=6455&amp;oldid=prev"/>
		<updated>2026-05-23T04:08:52Z</updated>

		<summary type="html">&lt;p&gt;parser-claude batch MedTemplate pre-fill, Top 300 #279&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{MedTemplate&lt;br /&gt;
| generic           = Cefuroxime (axetil oral, sodium IV)&lt;br /&gt;
| brand             = Ceftin (oral), Zinacef (IV)&lt;br /&gt;
| structure         =&lt;br /&gt;
| classes           = [[:Category:Cephalosporins|Cephalosporin (second-generation)]], [[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]]&lt;br /&gt;
| uses              = &amp;lt;vote slug=&amp;quot;otitis-media-use&amp;quot;&amp;gt;Acute otitis media&amp;lt;/vote&amp;gt;, &amp;lt;vote slug=&amp;quot;acute-bacterial-sinusitis-use&amp;quot;&amp;gt;Acute bacterial sinusitis&amp;lt;/vote&amp;gt;, &amp;lt;vote slug=&amp;quot;strep-pharyngitis-use&amp;quot;&amp;gt;Streptococcal pharyngitis&amp;lt;/vote&amp;gt;, &amp;lt;vote slug=&amp;quot;cap-use&amp;quot;&amp;gt;Community-acquired pneumonia (mild outpatient)&amp;lt;/vote&amp;gt;, &amp;lt;vote slug=&amp;quot;lyme-use&amp;quot;&amp;gt;Lyme disease (alternative to doxycycline)&amp;lt;/vote&amp;gt;, &amp;lt;vote slug=&amp;quot;early-uncomplicated-gonorrhea-use&amp;quot;&amp;gt;Uncomplicated gonorrhea (with azithromycin, historical; ceftriaxone now preferred)&amp;lt;/vote&amp;gt;&lt;br /&gt;
| starting_dose     = 250-500 mg PO BID × 7-14 days; IV 1.5 g q8h for serious infections&lt;br /&gt;
| preparations      = 125, 250, 500 mg tablets; 125 mg/5 mL, 250 mg/5 mL suspension; 750 mg, 1.5 g IV vials&lt;br /&gt;
| fda_max           = 1 g/d (oral); 6 g/d (IV)&lt;br /&gt;
| pill_id           =&lt;br /&gt;
| routes            = Oral, IV, IM&lt;br /&gt;
| onset             = Hours&lt;br /&gt;
| duration          = 8-12 hours&lt;br /&gt;
| halflife          = ~1.5 hours&amp;lt;ref name=&amp;quot;ceftin-label&amp;quot;&amp;gt;FDA Prescribing Information, Ceftin (cefuroxime axetil), GSK, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050605s039lbl.pdf&amp;lt;/ref&amp;gt;&lt;br /&gt;
| bioavailability   = ~37% (oral, as axetil prodrug; food modestly improves absorption)&amp;lt;ref name=&amp;quot;ceftin-label&amp;quot; /&amp;gt;&lt;br /&gt;
| pregnancy         = Generally considered safe in pregnancy.{{citation needed}}&lt;br /&gt;
| legal             = [[USLegal:Prescription only|Rx-only]] in US&lt;br /&gt;
| mechanism         = &amp;lt;vote slug=&amp;quot;cefuroxime-mech-claim&amp;quot;&amp;gt;Cefuroxime axetil is a prodrug hydrolyzed by intestinal esterases to cefuroxime; like all β-lactams it binds penicillin-binding proteins (PBPs) and inhibits transpeptidation of peptidoglycan cross-links, producing bactericidal cell wall destabilization.&amp;lt;/vote&amp;gt; Second-generation cephalosporin spectrum: improved gram-negative activity relative to first-generation cephalexin while retaining gram-positive activity and adding some β-lactamase stability. Cefuroxime crosses the blood-brain barrier sufficiently for Lyme disease but not reliably for bacterial meningitis (where third-generation agents are preferred)&amp;lt;ref name=&amp;quot;ceftin-label&amp;quot; /&amp;gt;.&lt;br /&gt;
}}&lt;br /&gt;
&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;/div&gt;</summary>
		<author><name>MDElliottMD</name></author>
	</entry>
</feed>